Effect of combined oral estrogen/progestogen preparation (Kliogest®) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women

Acta Obstetricia et Gynecologica Scandinavica

Volumn 82, Issue 9, 2003, Pages 857-866

  Jirapinyo, Mayuree ^a   Theppisai, Urusa ^a   Manonai, Jittima ^a   Suchartwatnachai, Charnchai ^a   Jorgensen, Lars Nelleman ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Novo Nordisk Pharma Singapore Pte Ltd   (Singapore)

Author keywords

Bone mineral density; Estrone; Kliogest ; Thai

Indexed keywords

CHOLESTEROL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BONE DENSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMALE; HIP; HUMAN; LIPOPROTEIN BLOOD LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOLYSIS; PRIORITY JOURNAL; THAILAND; UTERUS BLEEDING;

ADMINISTRATION, ORAL; AGED; BONE DENSITY; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESTRADIOL; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NORETHINDRONE; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTINS; THAILAND; TREATMENT OUTCOME; UTERINE HEMORRHAGE;

EID: 0042834306     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0412.2003.00185.x     Document Type: Article

References (30)

1. Ulrich LG, Barlow DH, Sturdee DW, Wells M, Campbell MJ, Nielsen B et al. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. Int J Gynaecol Obstet 1997; 59: S11-17.
2. Dören M, Reuther G, Minne HW, Schneider HP. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995; 173: 1446-51.
3. Christiansen C, Riis BJ. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836-41.
4. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 19: S191-3.
5. Limpaphayom KK, Bunyavejchevin S. Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women. J Med Assoc Thailand 2000; 83: 407-16.
6. Dören M, Schneider HP. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Maturitas 1996; 25: 99-105.
7. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Am Med Assoc 2000; 284: 3043-3045.
8. Grenne JG. Constructing a standard climacteric scale. Maturitas 1998; 29: 25-31.
9. Richmond W. Preparation and properties of a cholesteral oxidase from Norcadia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 1973; 19: 1350-6.
10. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80.
11. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women, the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32-47.
12. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc 1995; 273: 199-208.
13. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. J Am Med Assoc 1996; 276: 1389-96.
14. Munk Jensen N, Ulrich LG, Obel EB, Nielsen SP, Edwards D, Meinertz H. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect of plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994; 171: 132-8.
15. Chittacharoen A, Theppisai U, Sirisriro R, Thanantaseth C. Pattern of bone loss in surgical menopause: a preliminary report. J Med Assoc Thailand 1997; 80: 731-7.
16. Ongphiphadhanakul B, Piaseu N, Tung SS, Chailurkit L, Rajatanavin R. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen. Maturitas 2000; 34: 179-84.
17. Odell WE, Heath H. Osteoporosis: pathophysiology, prevention, diagnosis and treatment. Disease-a-Month 1993; 19: 789-98.
18. Prestwood K, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994; 79: 366-71.
19. Prestwood KM, Kenny AM, Unson C, Kulldorff M. The effect of low dose micronized 17β-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2000; 85: 4462-9.
20. Tikkanen MJ, Kuusi T, Nikkila EA, Sipinen S. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins - a review. Maturitas 1986; 8: 7-17.
21. Newnham HH. Ostrogens and atherosclerotic vascular disease: lipid factors. Bailliere's Clin Endocrinol Metab 1993; 7: 61-93.
22. Hart DM, Farish E, Fletcher CD, Barnes JF, Hart H, Nolan D et al. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women. Osteoporosis Int 1998; 8: 326-32.
23. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153: 2209-16.
24. Castelli WP. Cardiovascular death in women. Am J Obstet Gynecol 1988; 158: 1553-60.
25. Sanderson JE, Haines CJ, Yeung L, Yip GW, Tang K, Yim SF et al. Anti-ischemic action of estrogen-progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: a randomized, placebo-controlled, double-blind, parallel-group trial. J Cardiovasc Pharmacol 2001; 38: 372-83.
26. Boulet MJ, Oddens BJ, Lehert P, Vemer HM, Visser A. Climacteric and menopause in seven South-East Asian countries. Maturitas 1994; 19: 157-76.
27. Christiansen C, Christiansen MS, Transbol IB. Bone mass in postmenopausal women after withdrawal of estrogen replacement therapy. Lancet 1981; 1: 459-61.
28. Expert panel on detection, evaluation, and treatment of high cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult treatment panel III). J Am Med Assoc 2001; 285: 2486-97.
29. Pornel B, Chevallier O, Netelenbos JC. Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women. Menopause 2002; 9: 171-8.
30. Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000; 22: 622-36.